Form 4: MBX Biosciences Director Carl L. Gordon Reports Beneficial Ownership Changes After IPO

Following MBX Biosciences' initial public offering, director Carl L. Gordon reports changes in beneficial ownership of common stock and convertible preferred stock.

Summary

• Carl L. Gordon, a director of MBX Biosciences, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The changes occurred on September 16, 2024, coinciding with MBX Biosciences' initial public offering (IPO).
• Gordon's reported ownership includes common stock acquired through the conversion of preferred stock and purchases in the IPO.
• The transactions involve holdings by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P., for which OrbiMed Advisors exercises investment power.
• Gordon disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard procedures following an IPO. The sentiment is neutral to slightly positive as it reflects the completion of a significant corporate event.

Positives

• The report indicates participation in the IPO through the purchase of common stock.
• Conversion of preferred stock to common stock simplifies the capital structure post-IPO.

Industry Context

Form 4 filings are standard practice following significant events like IPOs, providing transparency into the ownership structure of the company.

Stakeholder Impact

• Provides shareholders with transparency regarding the ownership structure of the company post-IPO.

Key Dates